IDXX
IDEXX Laboratories Inc
527.10$
+1.7%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -8.3% | -20.5% | +25.0% | -11.4% | +19.1% | -9.2% | -21.9% | +116.6% | -12.5% | -24.4% | +30.4% | – | |
| – | +2.6% | +0.6% | +7.7% | +6.0% | -1.3% | +1.1% | +105.0% | -248.8% | – | -2.7% | +0.8% | – | |
| – | 0.0% | -5.4% | +9.2% | +1.3% | -10.4% | +2.5% | +101.6% | -249.6% | – | +1.4% | +4.0% | – | |
| – | +160.4% | -294.7% | – | -501.7% | – | – | – | – | -92.4% | -628.6% | – | – | |
| – | -4.5% | -7.0% | +10.0% | -15.7% | +39.8% | -23.5% | +13.6% | -8.8% | -5.4% | +8.7% | -22.9% | – | |
| – | +9.3% | +251.4% | -69.2% | -16.8% | +45.6% | -25.7% | +13.6% | +33.4% | -37.3% | +19.2% | -24.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +5.1% | +320.0% | +39.3% | +2.4% | +11.4% | +63.0% | -15.7% | -29.0% | -1.0% | +47.6% | -1.2% | – | |
| – | – | – | – | – | -100.0% | – | +124.6% | -179.4% | +6.5% | – | -108.3% | – | |
| – | +136.6% | +41.5% | +45.9% | +38.4% | -20.0% | +41.9% | -49.9% | +89.2% | +12.3% | -39.9% | +53.8% | – | |
| – | -38.5% | -146.2% | – | -2,336.1% | – | – | – | +6,882.7% | -164.5% | – | -117.6% | – | |
| – | -8.8% | -22.5% | +27.7% | -10.7% | +16.0% | -6.7% | -27.1% | +144.8% | -13.1% | -27.4% | +37.7% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.